Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30858| Title: | Gut microbiota - a double-edged sword in cancer immunotherapy. | Austin Authors: | Andrews, Miles C;Vasanthakumar, Ajithkumar | Affiliation: | Department of Medicine - Alfred, Monash University, Melbourne, Victoria, Australia. Olivia Newton-John Cancer Research Institute La Trobe University, Bundoora, Victoria, Australia |
Issue Date: | 2023 | Date: | 2022 | Publication information: | Trends in Cancer 2023; 9(1) | Abstract: | Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, many patients fail to respond to this therapy or experience side effects. Recently, gut microbiota have emerged as a key determinant of ICB efficacy and toxicity, making manipulation of the microbiome a novel therapeutic strategy with which to improve ICB outcomes. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/30858 | DOI: | 10.1016/j.trecan.2022.08.003 | Journal: | Trends in Cancer | PubMed URL: | 36088249 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.